Intranasal Brain Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Intranasal drug delivery represents a promising non-invasive approach for bypassing the blood-brain barrier (BBB) to deliver therapeutics directly to the brain. This route exploits the unique anatomical connections between the nasal cavity and the central nervous system, offering rapid brain access without the need for invasive procedures or systemic exposure[1].
The intranasal route utilizes two primary neural pathways to reach the brain:
The olfactory pathway provides direct access to the brain through the olfactory nerve. Molecules cross the olfactory epithelium, enter the olfactory nerve fibers, and are transported directly to the olfactory bulb and subsequent brain regions including the olfactory cortex, hippocampus, and amygdala[2].
The trigeminal nerve provides an additional route from the nasal cavity to the brainstem and thalamus. This pathway allows drugs to reach deeper brain structures including the cerebellum, hypothalamus, and cortical regions[3].
Intranasal insulin has been extensively studied for Alzheimer's disease and cognitive impairment:
Oxytocin, a neuropeptide involved in social cognition and anxiety, has been delivered intranasally for:
| Strategy | Mechanism | Examples |
|---|---|---|
| Mucoadhesive gels | Prolong nasal residence time | Chitosan, carbopol, hyaluronic acid |
| Nanoparticles | Enhance epithelial transport | PLGA, solid lipid nanoparticles |
| Absorption enhancers | Open tight junctions | Cyclodextrins, surfactants |
| Enzyme inhibitors | Protect payload degradation | Protease inhibitors |
| Permeation enhancers | Increase membrane fluidity | Fatty acids, bile salts |
Cyclodextrins (particularly hydroxypropyl-β-cyclodextrin) form inclusion complexes with lipophilic drugs, improving solubility and nasal absorption. They also have neuroprotective properties and are being investigated for treating Niemann-Pick disease type C[10].
Chitosan-based formulations are widely used due to their:
The POD device delivers aerosolized medication specifically to the olfactory region using pressurized metered-dose inhaler technology. This targeted approach improves olfactory delivery efficiency compared to conventional nasal sprays[11].
OptiMist uses electronic micro-pumps to generate fine aerosol particles optimized for deposition in the olfactory epithelium. The device allows for precise dose control and consistent delivery[12].
| Trial | Compound | Indication | Phase | Key Findings |
|---|---|---|---|---|
| SNIFF | Insulin glulisine | AD/MCI | Phase 2/3 | Improved cognition at 20-40 IU/day |
| NCT00846040 | Insulin aspart | AD | Phase 2 | Safe, improved memory performance |
| NCT01767909 | Insulin lispro | AD | Phase 2 | Dose-dependent cognitive benefits |
| NCT01547273 | Oxytocin | ASD | Phase 2 | Improved social cognition |
| NCT02054069 | BDNF | PD | Phase 1 | Safety established |
| Route | BBB Crossing | Onset | Invasiveness | Key Limitations |
|---|---|---|---|---|
| Intranasal | Direct | Minutes | None | Limited volume, anatomical reach |
| Intravenous + BBB shuttle | Receptor-mediated | Hours | Moderate | Requires engineered molecules |
| Intrathecal | Direct (CSF) | Hours-Days | High | Infection risk, distribution limited |
| Convection-enhanced | Direct | Hours | High | Surgical risk, catheter placement |
| Focused ultrasound | Temporary opening | Hours | Moderate | Equipment cost, safety |
The study of Intranasal Brain Delivery has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page created: 2026-03-05
Last updated: 2026-03-05
Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614-628. DOI:10.1016/j.addr.2011.11.002 ↩︎
Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654-1673. DOI:10.1002/jps.21924 ↩︎
Johnson NJ, Hanson LR, Frey WH. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and liver. J Drug Target. 2010;18(2):118-126. DOI:10.3109/10611860903311564 ↩︎
Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated neural pathways: A promising strategy for brain disorders. J Mater Sci: Mater Med. 2018;29(8):120. DOI:10.1007/s10856-018-6102-4 ↩︎
Chapman CD, Frey WH, Craft S, et al. Intranasal insulin in older adults: A window to the brain? J Diabetes Sci Technol. 2013;7(5):1245-1255. DOI:10.1177/193229681300700513 ↩︎
Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A randomized clinical trial. JAMA Neurol. 2012;69(1):29-38. DOI:10.1001/jamaneurol.2011.233 ↩︎
Craft S, Claxton A, Baker LD, et al. Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: A pilot clinical trial. J Alzheimers Dis. 2017;57(4):1325-1334. DOI:10.3233/JAD-161256 ↩︎
Kramer BM, Van der Zee CE, Hagg T. Nerve growth factor and Alzheimer's disease: At the interface between central and peripheral nervous system therapy. CNS Drugs. 1999;12(2):123-140. ↩︎
Jiang Y, Liu L, Pagadala J, et al. Intranasal delivery of stem cell-based therapies for the treatment of CNS disorders. Mol Ther. 2021;29(1):23-40. DOI:10.1016/j.ymthe.2020.10.019 ↩︎
Matsuda K, Murasaki M, Yamaguchi K, et al. Intranasal delivery of hydroxypropyl-β-cyclodextrin: A novel therapeutic approach for Niemann-Pick disease type C. Mol Ther. 2020;28(9):2053-2065. DOI:10.1016/j.ymthe.2020.06.015 ↩︎
Hoekman JD, Ho RJ. Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. J Pharm Sci. 2011;100(3):1087-1095. DOI:10.1002/jps.22326 ↩︎
Wang D, Narang AS, Kotyla T, et al. Improved intranasal delivery of recombinant human BDNF with nanoemulsion. J Drug Target. 2022;30(2):189-202. DOI:10.1080/1061186X.2021.1955188 ↩︎